Can Less Be More? Reduced GLP-1 Dosing May Sustain – and Even Enhance – Weight Loss
Key Takeaways:
- Structured reduction in GLP-1 receptor agonist dosing frequency may allow continued weight loss while lowering treatment burden
- Cardiometabolic improvements achieved during weekly dosing appear to be maintained with less frequent dosing
- Early evidence suggests some individuals may not require high or frequent dosing to sustain weight loss, although larger trials are needed
A new approach to GLP-1 treatment
Emerging evidence suggests that reducing the frequency of glucagon-like peptide-1 receptor agonist (GLP-1 RA) dosing may still deliver sustained benefits for people living with obesity. Data presented at the Obesity Medicine Association’s annual conference indicate that a structured, gradual de-escalation strategy could maintain, and in some cases enhance, weight loss outcomes while reducing the burden of ongoing treatment.
This finding challenges the prevailing assumption that continuous, high-frequency dosing is required to preserve the benefits of these therapies.
Continued weight loss despite reduced dosing
The research, led by Mitch Biermann, MD, PhD, examined outcomes in individuals who transitioned from weekly GLP-1 RA dosing to less frequent schedules. Reflecting on the results, Biermann noted:
“What I found was actually surprising, where in addition to losing weight initially on the weekly regimen, people actually lost further weight on the every-other-week regimen,” Mitch Biermann, MD, PhD, an obesity medicine physician and scientist at Scripps Health, told Healio. “I was just hoping people would break even, not get an additional 2% weight loss.”
This observation suggests that, for some individuals, reduced dosing frequency does not simply preserve prior weight loss but may contribute to further reductions.
Addressing a common patient concern
The study was partly motivated by a frequent question from patients considering GLP-1 therapy. As Biermann explained:
“The No. 1 question patients have when they’re deciding to start one of these medicines is, ‘Do I have to be on this every week for the rest of my life? Do I have to take this forever?’” he said. “Patients ask that about certain medicines and not others. It usually correlates with the stigma around the disease. They always ask about it for weight loss medicine.”
This highlights an important dimension of obesity care – long-term treatment expectations and the role of stigma in shaping patient concerns.
Study design and patient cohort
The analysis was based on a retrospective case series involving 30 adults who had been prescribed either semaglutide (Wegovy or Ozempic) or tirzepatide (Mounjaro). All participants had experienced a plateau in weight loss during standard weekly treatment.
Participants agreed to reduce their dosing frequency while maintaining their effective dose. The adjusted schedules included:
- Every 10 to 14 days (n = 6)
- Every two weeks (n = 17)
- Longer than every two weeks (n = 7)
The mean follow-up period was 36 weeks.
Body composition and weight outcomes
Following the transition to reduced dosing, participants continued to lose weight, with reported reductions of 72.4 ± 2.2 kg (P < .01). In addition to overall weight loss, improvements were observed in body composition:
- Reductions in body fat mass
- Decreases in average percentage body fat
- Lower truncal fat mass
At the same time, skeletal muscle mass increased slightly from 30.33 ± 1.27 to 30.63 ± 1.25, suggesting that weight loss was not associated with disproportionate muscle loss.
Sustained cardiometabolic benefits
Importantly, key metabolic improvements achieved during weekly dosing were maintained after reducing treatment frequency:
- Glycaemic control: HbA1c improved from 5.6% ± 0.13% before treatment to 5.1% ± 0.1% during weekly dosing (P < .001), with no change during reduced dosing
- Triglycerides: Levels decreased from 121 ± 11.3 mg/dL to 84.3 ± 9.6 mg/dL during weekly dosing (P < .001) and remained stable at 74.8 ± 4.1 mg/dL
- Mean arterial pressure: Reduced from 90.5 ± 2 mm Hg to 84.8 ± 2.1 mm Hg (P < .05), remaining stable at 85.1 ± 1.5 mm Hg during maintenance
The proportion of participants meeting criteria for metabolic syndrome also declined, from nearly 83% before treatment to 68% during weekly dosing and 58.6% following dose reduction.
Interpreting the findings
The study authors suggest that lower levels of GLP-1 receptor stimulation may be sufficient to maintain weight loss once it has been achieved. Biermann offered the following interpretation:
“that you don’t need much of these hormones to maintain weight loss, even though you need a lot of them to reduce weight.”
He also drew a parallel with physical activity:
“Exercise doesn’t cause people to lose a ton of weight. It causes people to maintain their weight if they lose it by another method for the most part,” he said. “And that matches this hormone data, because that 30% increase [in hormone levels] you get on GLP-1s from exercise is probably enough to maintain your weight loss.”
Limitations and considerations
The findings should be interpreted cautiously. The study was small, non-randomised, and based on a retrospective case series. In addition, the cohort lacked diversity, with only four participants not identified as white and just two individuals living with class II or III obesity.
These limitations mean that the results may not be generalisable to broader populations.
Implications for clinical practice
Despite its limitations, the study offers a potentially important insight into long-term obesity management. Gradual dose reduction may represent a viable strategy for some individuals seeking to balance efficacy with treatment burden.
As Biermann concluded:
“I think it’s an option that works for many people, [particularly] when we don’t study how to stop medicine in general,” Biermann told Healio.
“I think it’s nice to have some published data on the average effectiveness of this strategy, even though it’s not a randomized controlled trial,” he said.
Looking ahead
Further research, particularly large-scale randomised controlled trials, will be essential to determine whether reduced dosing strategies can be safely and effectively implemented in routine care. For now, these findings provide an early signal that long-term GLP-1 therapy may not need to follow a one-size-fits-all model.
Source: Healio
